Giuseppe Remuzzi

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. pmc Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    PLoS ONE 7:e32533. 2012
  2. pmc Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 33:1954-6. 2010
  3. pmc Prevalence of hypertension and diabetes and coexistence of chronic kidney disease and cardiovascular risk in the population of the republic of moldova
    Igor Codreanu
    Republican Clinic Hospital, Chisinau, Moldova
    Int J Hypertens 2012:951734. 2012
  4. doi request reprint Kidney failure: aims for the next 10 years and barriers to success
    Giuseppe Remuzzi
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Lancet 382:353-62. 2013
  5. doi request reprint Mechanisms and treatment of CKD
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Am Soc Nephrol 23:1917-28. 2012
  6. doi request reprint Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Stem Cells 28:513-22. 2010
  7. ncbi request reprint V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction
    Norberto Perico
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 76:960-7. 2009
  8. ncbi request reprint Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin
    Cristina Zanchi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Immunol 181:1460-9. 2008
  9. pmc Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Via Camozzi, 3 24020 Ranica Bg, Italy
    Clin J Am Soc Nephrol 5:1844-59. 2010
  10. doi request reprint Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
    Elena Gagliardini
    Mario Negri Institute for Pharmacological Research, University of Bergamo, Bergamo, Italy
    Am J Physiol Renal Physiol 297:F1448-56. 2009

Detail Information

Publications121 found, 100 shown here

  1. pmc Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    PLoS ONE 7:e32533. 2012
    ..Direct kidney function measurements by appropriate techniques are needed to adequately evaluate treatment effects in clinics and research...
  2. pmc Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 33:1954-6. 2010
    ..To assess the effects of inhibited gastrointestinal cholesterol absorption in statin-treated dyslipidemic patients...
  3. pmc Prevalence of hypertension and diabetes and coexistence of chronic kidney disease and cardiovascular risk in the population of the republic of moldova
    Igor Codreanu
    Republican Clinic Hospital, Chisinau, Moldova
    Int J Hypertens 2012:951734. 2012
    ....
  4. doi request reprint Kidney failure: aims for the next 10 years and barriers to success
    Giuseppe Remuzzi
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Lancet 382:353-62. 2013
    ....
  5. doi request reprint Mechanisms and treatment of CKD
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Am Soc Nephrol 23:1917-28. 2012
    ..Whether novel medications may help further improve the cost-effectiveness of renoprotective interventions is a matter of investigation...
  6. doi request reprint Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Stem Cells 28:513-22. 2010
    ..Altogether these results highlight the potential of human CB-MSCs as future cell therapy for testing in human AKI...
  7. ncbi request reprint V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction
    Norberto Perico
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 76:960-7. 2009
    ..Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy...
  8. ncbi request reprint Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin
    Cristina Zanchi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Immunol 181:1460-9. 2008
    ..coli O157:H7 infection...
  9. pmc Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Via Camozzi, 3 24020 Ranica Bg, Italy
    Clin J Am Soc Nephrol 5:1844-59. 2010
    ..Most childhood cases are caused by Shiga toxin-producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS...
  10. doi request reprint Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
    Elena Gagliardini
    Mario Negri Institute for Pharmacological Research, University of Bergamo, Bergamo, Italy
    Am J Physiol Renal Physiol 297:F1448-56. 2009
    ..These findings provide mechanistic insights to explain the antiproteinuric effect of this combined therapy in diabetes...
  11. doi request reprint Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat
    Anna Pezzotta
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Transplantation 85:1476-82. 2008
    ..T cell stimulation by alloantigens is followed by cell cycle progression, an event that is critically dependent on cyclin-dependent kinases...
  12. ncbi request reprint Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Arthritis Rheum 56:1629-37. 2007
    ..To examine whether the cyclin-dependent kinase (CDK) inhibitor seliciclib ameliorates autoimmune nephritis in (NZB x NZW)F(1) mice...
  13. pmc ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy
    Erica Rurali
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Diabetes 62:3599-609. 2013
    ..Screening for Pro618Ala polymorphism may help identify patients with diabetes at highest risk who may benefit the most from early reno- and cardioprotective therapy. ..
  14. ncbi request reprint Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells
    Susanna Tomasoni
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1056-61. 2005
    ....
  15. doi request reprint Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 303:F1370-81. 2012
    ....
  16. pmc In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 166:1309-20. 2005
    ..Increased ET-1 generation might alter glomerular permselectivity and amplify the noxious effect of protein overload on dysfunctional podocytes...
  17. doi request reprint Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87, 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 299:F1203-11. 2010
    ..These data suggest a strategy to target proteinuria to try to achieve regression of renal disease in diabetic patients who do not fully benefit from RAS inhibition alone...
  18. pmc Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 169:1965-75. 2006
    ..These data suggest that the podocyte is a target of Stx, a novel stimulus for the synthesis of ET-1, which may control cytoskeleton remodeling and glomerular permeability in an autocrine fashion...
  19. ncbi request reprint Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings
    Eliana Gotti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Italy
    J Am Soc Nephrol 14:755-66. 2003
    ..CsA reduction did not adversely affect histology. Per-protocol biopsy more than 1 yr after kidney transplantation is a safe procedure to guide change of drug regimen and to lower the risk of major side effects...
  20. ncbi request reprint Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial
    Giuseppe Remuzzi
    Department of Renal Medicine, Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 18:1973-85. 2007
    ..In view of the cost, standard immunosuppression regimens for kidney transplantation should perhaps include azathioprine rather than MMF...
  21. ncbi request reprint DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties
    Sistiana Aiello
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 83:474-84. 2007
    ..Here we investigate the potency, the phenotype, and the mechanism of action of dnIKK2-DC-induced regulatory cells and we evaluated their tolerogenic properties in vivo...
  22. ncbi request reprint Regulatory T cells and T cell depletion: role of immunosuppressive drugs
    Marina Noris
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 18:1007-18. 2007
    ..These findings will be instrumental in developing "tolerance permissive" immunosuppressive regimens in the clinical setting...
  23. doi request reprint Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Kidney Int 81:903-18. 2012
    ..Thus non-erythropoietic derivatives of EPO may be useful to prevent chronic renal allograft injury...
  24. ncbi request reprint Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Bergamo, Italy
    Transplantation 84:956-64. 2007
    ..This might translate into more effective protection against chronic graft injury compared to cyclosporin A (CsA), which, in the same clinical setting, does not affect Treg...
  25. pmc Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
    Jessica Caprioli
    Mario Negri Institute for Pharmacologic Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Bergamo, Italy
    Blood 108:1267-79. 2006
    ..Hopefully this will translate into improved management and therapy of patients and will provide the way to design tailored treatments...
  26. ncbi request reprint Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Nephron Exp Nephrol 104:e158-68. 2006
    ..We investigated whether in a two-kidney diabetic model the time at which treatment started predicted the response to TGFbeta antagonist...
  27. pmc Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 5:1928-38. 2010
    ....
  28. doi request reprint Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells
    Simona Buelli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 75:1050-9. 2009
    ..Thus, protein overload reduces the ability of the tubule cell to bind factor H and counteract complement activation, effects instrumental to renal disease progression...
  29. pmc Sirolimus therapy to halt the progression of ADPKD
    Norberto Perico
    Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 21:1031-40. 2010
    ..In summary, sirolimus halted cyst growth and increased parenchymal volume in patients with ADPKD. Whether these effects translate into improved long-term outcomes requires further investigation...
  30. ncbi request reprint Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 66:1959-65. 2004
    ....
  31. doi request reprint Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy
    Am J Physiol Renal Physiol 304:F808-19. 2013
    ..Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy...
  32. doi request reprint The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts
    Marina Noris
    Transplant Research Center Chiara Cucchi De Alessandri and Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Via Camozzi 3, 24020 Ranica, Bergamo, Italy
    J Immunol 183:4249-60. 2009
    ..Thus, TIR8 acts locally as a key regulator of allogeneic immune response in the kidney. Tir8 expression and/or signaling in donor tissue are envisaged as a novel target for control of innate immunity and amelioration of graft survival...
  33. pmc Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis
    Mauro Abbate
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 161:2179-93. 2002
    ..Agents to reduce TGF-beta1, possibly combined with angiotensin blockade, should have priority in novel approaches to treatment of progressive nephropathies...
  34. ncbi request reprint Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Stem Cells 26:2075-82. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  35. pmc Disruption of the Ang II type 1 receptor promotes longevity in mice
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy
    J Clin Invest 119:524-30. 2009
    ....
  36. ncbi request reprint Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
    Ruth Campbell
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 63:1094-103. 2003
    ..Proteinuria predicts renal disease progression, and its reduction by angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA) is renoprotective...
  37. doi request reprint Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation
    Norberto Perico
    Department of Immunology and Transplantation, Azienda Ospedaliera IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Transpl Int 26:867-78. 2013
    ..Induction therapy without basiliximab does not offer any advantage on CD4(+) FoxP3(+) Treg expansion (ClinicalTrials.gov number: NCT 00752479)...
  38. doi request reprint The GFR and GFR decline cannot be accurately estimated in type 2 diabetics
    Flavio Gaspari
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 84:164-73. 2013
    ..Thus, our study questions the use of any estimation formula to identify hyperfiltering patients and monitor renal disease progression and response to treatment in type 2 diabetics without overt nephropathy. ..
  39. ncbi request reprint Preventing microalbuminuria in type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy
    N Engl J Med 351:1941-51. 2004
    ....
  40. pmc Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Department of Biomedical Engineering, Laboratory of Renal Biophysics, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Am J Pathol 174:797-807. 2009
    ..Increased parietal podocyte number in lisinopril-treated MWF rats suggests that the remodeling of Bowman's capsule epithelial cells contributes to this effect...
  41. ncbi request reprint Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Bergamo, Italy
    Kidney Int 65:2193-200. 2004
    ..Here we addressed the role of nephrin, CD2-associated protein (CD2AP), and podocin together with the integrity of the slit diaphragm in the pathogenesis of proteinuria of patients with diabetes and nephropathy...
  42. ncbi request reprint Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, 11 24125 Bergamo, Italy
    J Am Soc Nephrol 17:1665-72. 2006
    ....
  43. ncbi request reprint The RAAS in the pathogenesis and treatment of diabetic nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Nat Rev Nephrol 6:319-30. 2010
    ..Such findings will have major implications, particularly in settings where money and facilities are limited and in settings where renal replacement therapy is not available and the prevention of kidney failure is life saving...
  44. pmc Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility
    Norberto Perico
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Department of Immunology and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Parco Scientifico Tecnologico Kilometro Rosso, via Stezzano 87, 24126 Bergamo, Italy
    Clin J Am Soc Nephrol 6:412-22. 2011
    ..Mesenchymal stromal cells (MSCs) abrogate alloimmune response in vitro, suggesting a novel cell-based approach in transplantation. Moving this concept toward clinical application in organ transplantation should be critically assessed...
  45. ncbi request reprint Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi Ranica, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 16:1177-83. 2005
    ..In addition, a heterozygous mutation (causing an S890I change) in factor H of complement was found in the patient who developed chronic renal failure but not in her sister, who presented with exclusive neurologic symptoms...
  46. pmc Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 3:1652-9. 2008
    ..Whether this is associated with kidney function restoration and regression of the glomerular pathology was evaluated...
  47. doi request reprint Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Via Camozzi, Bergamo, Italy
    Transplantation 92:271-9. 2011
    ..Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients...
  48. ncbi request reprint Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 365:939-46. 2005
    ....
  49. pmc Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 168:1073-85. 2006
    ..These data demonstrate that strategies aimed at stabilizing podocyte-podocyte contacts and targeting the relevant intracellular signal transduction are crucial to renoprotection...
  50. ncbi request reprint Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1816-24. 2003
    ....
  51. ncbi request reprint Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 17:3472-81. 2006
    ..As compared with trandolapril, Veratran may help with achievement of target BP with less need for concomitant antihypertensive medications...
  52. ncbi request reprint Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Hypertens 29:207-16. 2011
    ..To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients...
  53. doi request reprint Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica, Bergamo, Italy
    Hypertension 58:776-83. 2011
    ..In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity...
  54. pmc Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases, Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 31:1629-34. 2008
    ..We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH)...
  55. ncbi request reprint Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival
    Susanna Tomasoni
    Mario Negri Institute for Pharmacological Research, Institute for Pharmacological Research, Bergamo, Italy
    Am J Nephrol 24:275-83. 2004
    ..Since we previously demonstrated that transfection of the donor kidney with CTLA4Ig significantly prolonged allograft survival, we also evaluated the effect of a combined injection of AdvIL-10 or AdTGF-beta3 with the AdCTLA4Ig...
  56. pmc Role of remission clinics in the longitudinal treatment of CKD
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1213-24. 2008
    ....
  57. pmc ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 20:1404-15. 2009
    ..Genetic evaluation may help to identify patients at risk and to modulate CsA therapy to optimize graft and patient outcomes...
  58. pmc Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway
    Elena Gagliardini
    Mario Negri Institute of Pharmacology Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy
    Am J Pathol 183:119-30. 2013
    ....
  59. ncbi request reprint Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
    ..The meta-analyses, however, represent a valuable tool to evaluate the consistency and generalizability of trial results to larger cohorts of patients...
  60. ncbi request reprint Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells
    Regiane Aparecida Cavinato
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1034-9. 2005
    ..It was suggested that maintenance of tolerance to organ transplantation may depend on the formation of T regulatory cells...
  61. ncbi request reprint Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats
    Anna Pezzotta
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Transplantation 80:231-6. 2005
    ..The aim of the present study was to investigate the effects of this drug on allogeneic immune response and on renal allograft survival in rats...
  62. ncbi request reprint Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation
    Daniela Corna
    Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Nephrol 27:630-8. 2007
    ..However, some safety concerns have been recently raised on the use of these agents, mainly due to transient episodes of proteinuria observed in patients receiving high doses of rosuvastatin...
  63. pmc Glomerular hyperfiltration and renal disease progression in type 2 diabetes
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 35:2061-8. 2012
    ..To describe the prevalence and determinants of hyperfiltration (glomerular filtration rate [GFR] ≥120 mL/min/1.73 m(2)), GFR decline, and nephropathy onset or progression in type 2 diabetic patients with normo- or microalbuminuria...
  64. doi request reprint Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model
    Fabio Sangalli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Physiol Renal Physiol 300:F1291-300. 2011
    ..They also suggest that evaluation of tubular protein concentration levels could help to identify patients at risk of kidney disease progression and to improve clinical management...
  65. ncbi request reprint How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 13:2898-908. 2002
    ..These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy...
  66. ncbi request reprint Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 64:857-63. 2003
    ..Since biologic effects and production of ET-1 within the kidney are counteracted by nitric oxide, we studied the effect of combining lisinopril and l-arginine, the natural precursor of nitric oxide, starting late in the disease...
  67. ncbi request reprint Kidney failure stabilizes after an increase over 2 decades
    Paolo Cravedi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Care 33:100-4. 2007
    ..Early intervention may be important to maximize renoprotection, especially in diabetics...
  68. ncbi request reprint Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 364:503-12. 2004
    ..We aimed to compare the antirejection activity of these two drugs with a new formulation of ciclosporin...
  69. ncbi request reprint Insulin-like growth factor-1 sustains stem cell mediated renal repair
    Barbara Imberti
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 18:2921-8. 2007
    ..These findings indicate that MSC exert beneficial effects on tubular cell repair in acute kidney injury by producing the mitogenic and pro-survival factor IGF-1...
  70. ncbi request reprint Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin Chim Acta 355:153-64. 2005
    ..Immunoassays used for the measurement of cyclosporine (CsA) usually show cross-reactivity for CsA metabolites, usually resulting in unacceptable bias...
  71. doi request reprint Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Nephrol 33:461-8. 2011
    ..Here we evaluated whether rituximab is equally effective in patients who failed to respond to previous immunosuppressive treatment...
  72. ncbi request reprint Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
    Aneliya Parvanova
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Villa Camozzi, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Expert Opin Pharmacother 6:1931-42. 2005
    ..Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown...
  73. ncbi request reprint C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation
    Sara Baldelli
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Via Gavazzeni, 11 24125 Bergamo, Italy
    Pharmacogenomics 8:1127-41. 2007
    ..Several polymorphisms in the genes encoding for UGT1A9, UGT2B7 and MRP2 proteins have been described. However, their functional role in vivo on MPA metabolism remains poorly defined...
  74. ncbi request reprint Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model
    Borislav D Dimitrov
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Nephron Clin Pract 95:c47-59. 2003
    ..To predict risk of end-stage renal disease (ESRD) in individual patients with chronic nephropathy...
  75. doi request reprint Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, 24126 Bergamo, Italy
    J Immunol 187:172-80. 2011
    ..These results identify Stx-induced complement activation, via P-selectin, as a key mechanism of C3a-dependent microvascular thrombosis in diarrhea-associated HUS...
  76. ncbi request reprint Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 15:2666-74. 2004
    ..These findings provide a clear rationale for specifically targeting proteinuria in pharmacologic interventions of chronic nephropathies...
  77. pmc Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients
    Anna Caroli
    Department of Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Pathol 179:619-27. 2011
    ..79, P < 0.005). These findings suggest that intermediate volume may represent a suitable surrogate marker of ADPKD progression and a novel therapeutic target...
  78. ncbi request reprint Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Ther Drug Monit 28:643-9. 2006
    ..This would imply the need of specific algorithms to adequately estimate CsA dose adjustment in patients given, in addition to CsA, EC-MPS or MMF...
  79. doi request reprint Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation
    Nadia Azzollini
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 74:1420-8. 2008
    ..The efficacy of propionyl-L-carnitine to modulate ischemia-reperfusion injury during transplantation suggests that its use in human transplantation is worth testing...
  80. pmc Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 20:123-30. 2009
    ..These data suggest that albumin can be a source of potentially antigenic peptides upon renal injury and that renal DC play a role in processing self-proteins through a proteasome-dependent pathway...
  81. ncbi request reprint Familial haemolytic uraemic syndrome and an MCP mutation
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi Ranica, Bergamo, Italy
    Lancet 362:1542-7. 2003
    ..However, most patients with D-HUS have no HF1 mutations, despite decreased serum concentrations of C3. Our aim, therefore, was to assess whether genetic abnormalities in other complement regulatory proteins are involved...
  82. doi request reprint Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation
    Sistiana Aiello
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Transpl Int 24:829-38. 2011
    ..If these results will be translated into the clinical setting, pretransplant administration of Thymoglobuline(®) could offer the additional advantage over peri-transplant administration of limiting I/R-mediated kidney graft damage...
  83. ncbi request reprint Long-term outcome of renal transplantation from older donors
    Giuseppe Remuzzi
    Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    N Engl J Med 354:343-52. 2006
    ..We sought to determine whether selecting older kidneys according to their histologic characteristics before implantation would positively influence long-term outcome...
  84. pmc Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity
    Ariela Benigni
    Department of Molecular Medicine, Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, via Stezzano 87, 24126, Bergamo, Italy
    Age (Dordr) 35:993-1005. 2013
    ..Moreover, rs275653 was associated to lower blood pressure in centenarians. These findings highlight the role of AGTR1 as a possible candidate among longevity-enabling genes...
  85. doi request reprint Hepatitis C infection and chronic renal diseases
    Norberto Perico
    Department of Medicine and Transplantation Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 4:207-20. 2009
    ....
  86. doi request reprint Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy
    Hypertension 54:567-74. 2009
    ..Whether these effects may translate into long-term cardioprotection is worth investigating...
  87. pmc Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Bergamo, Italy
    Am J Pathol 179:628-38. 2011
    ..ACEi, by moderating progenitor cell activation, restores glomerular architecture and prevents renal disease progression...
  88. ncbi request reprint Performance of different prediction equations for estimating renal function in kidney transplantation
    Flavio Gaspari
    Department of Medicine and Transplantation, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Transplant 4:1826-35. 2004
    ..In clinical trials of kidney transplantation, graft function should be preferably monitored using a reference method of GFR measurement, such as iohexol plasma clearance...
  89. ncbi request reprint Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 15:1794-804. 2004
    ..These results offer a strong case for exploring the possibility that mesenchymal stem cells by virtue of their renotropic property and tubular regenerative potential may have a role in the treatment of acute renal failure in humans...
  90. ncbi request reprint Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute, Bergamo, Italy
    Circulation 107:586-92. 2003
    ..Dyslipidemia frequently complicates chronic nephropathies and increases the risk of renal and cardiovascular events. This might be ameliorated by drugs, such as angiotensin-converting enzyme inhibitors, which effectively reduce proteinuria...
  91. pmc Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori Science and Technology Park, Kilometro Rosso Via Stezzano 87, Bergamo, Italy
    J Am Soc Nephrol 23:1717-24. 2012
    ..Taken together, among normoalbuminuric patients with type 2 diabetes, any degree of measurable albuminuria bears significant cardiovascular risk. The association with risk is continuous but is lost with early ACEI therapy...
  92. ncbi request reprint ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established
    Marina Noris
    Department of Medicine and Transplantation, Ospedali Riuniti Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 64:2253-61. 2003
    ..Whether this therapeutic approach is effective even if started when signs of allograft nephropathy are already manifested has not been investigated...
  93. pmc MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Via Stezzano, 87 24126 Bergamo, Italy
    J Am Soc Nephrol 23:1496-505. 2012
    ..The renoprotective effects of ACE inhibitors may result, in part, from modulation of this pathway, suggesting that it may hold other potential therapeutic targets...
  94. ncbi request reprint Effect of inborn pancreatic islet deficit in the Munich Wister Frömter rat
    Marina Figliuzzi
    Department of Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Islets 2:318-22. 2010
    ..These data suggest that an inborn deficit in β cell mass of about 60% is responsible for altered glucose metabolism and could favor the development of diabetes...
  95. ncbi request reprint In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura
    Roberta Donadelli
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Villa Camozzi, Via Camozzi, 3, 24020 Ranica, Bergamo, Italy
    Thromb Haemost 96:454-64. 2006
    ..In conclusion, defective secretion and impaired activity of the mutants concur to determine an almost complete deficiency of ADAMTS13 activity in patients with a homozygous or two heterozygous ADAMTS13 mutations...
  96. doi request reprint Aldosterone and progression of kidney disease
    Monica Cortinovis
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Ther Adv Cardiovasc Dis 3:133-43. 2009
    ..Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases...
  97. pmc In vivo maturation of functional renal organoids formed from embryonic cell suspensions
    Christodoulos Xinaris
    Department of Molecular Medicine, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 23:1857-68. 2012
    ..The ability to generate vascularized nephrons from single-cell suspensions marks a significant step to the long-term goal of replacing renal function by a tissue-engineered kidney...
  98. doi request reprint Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy
    Am J Physiol Renal Physiol 301:F1114-23. 2011
    ..The drug combination also showed cardioprotective properties, which however, were mainly dependent on the contribution of the ET(A) receptor antagonist through the action of VEGF...
  99. pmc Angiotensin II revisited: new roles in inflammation, immunology and aging
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    EMBO Mol Med 2:247-57. 2010
    ..This review extends from the discovery of Ang II and its implications in renal and cardiovascular physiology to cover the roles of the system in inflammation, tissue injury, autoimmunity, oxidative stress and aging...
  100. ncbi request reprint Investigational drugs for diabetic nephropathy
    Monica Cortinovis
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Investig Drugs 17:1487-500. 2008
    ..Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality...
  101. pmc Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide
    Anna Caroli
    Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Clin J Am Soc Nephrol 5:783-9. 2010
    ..In a prospective, randomized, double-blind, crossover study, 6 months of octreotide (40 mg every 28 days) therapy limited kidney volume growth more effectively than placebo in 12 patients with ADPKD...